Concord Drugs Announces Q1 Financial Results: Flat Performance with Positive Sales Trend

Concord Drugs, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending March 2024. According to the report, the company has seen a flat performance in this quarter, with a score of -2, which is an improvement from the previous quarter's score of -9.

Despite the overall flat performance, there are some positive aspects to note from the financials. The company's net sales for the quarter were the highest in the last five quarters, at Rs 15.64 crore. This is a 27.05% increase from the same quarter last year, indicating a positive sales trend in the near term.

However, there are also some areas of concern for Concord Drugs. The operating profit (PBDIT) for the quarter was the lowest in the last five quarters, at Rs 0.34 crore. This indicates a negative trend in the near term for the company's operating profit. Additionally, the operating profit margin was also the lowest in the last five quarters, at 2.17%, showing a decline in the company's efficiency.

The profit before tax (PBT) less other income for the quarter was also the lowest in the last five quarters, at Rs -0.55 crore. This indicates a negative trend in the near term for the company's PBT. The earnings per share (EPS) for the quarter were also the lowest in the last five quarters, at Rs -0.34. This shows a decline in profitability and lower earnings for shareholders.

Based on these financial results, MarketsMOJO has given a stock call of 'Sell' for Concord Drugs. Investors should carefully consider these factors before making any investment decisions.